SOMI (Somnia) fluctuated by 43.2% in 24 hours: trading volume surged over 1700% driving the rebound
Bitget Pulse2026/04/26 22:03Volatility Overview
In the past 24 hours, SOMI rebounded from a low of $0.1783 to a high of $0.2554, currently quoted at $0.1835, with a price fluctuation amplitude of 43.2%, showing a sharp rise followed by a slight pullback. The 24-hour trading volume surged to approximately $97.65 million, up 1781.5% from the previous day, with obvious net capital inflow, indicating significantly increased market activity.
Analysis of Unusual Movements
• Trading volume soared: 24-hour trading volume reached $97.65 million, an increase of over 1700%, directly driving the price rebound and amplifying volatility.
• No explicit official announcements or on-chain large whale movements have been recorded; the volatility is mainly driven by market trading.
Market View and Outlook
Market sentiment is bullish, with traders focusing on the stability of the $0.1684-$0.1703 support zone. The short-term bullish target is $0.1763-$0.1850, and some views are signaling a potential reversal. Caution is advised regarding the potential selling pressure from the unlocking of approximately 9.35 million tokens on May 2.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
